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Abstract 
 
Rationale 
Anticipatory nausea (AN) is a poorly controlled side-effect experienced by 
chemotherapy patients. Currently, pharmacotherapy is restricted to benzodiazepine 
anxiolytics, which have limited efficacy, significant sedative effects, and induce 
dependency. The non-psychoactive phytocannabinoid, cannabidiolic acid (CBDA), 
has shown considerable efficacy in pre-clinical AN models, however determination of 
its neuromotor tolerability profile is crucial to justify clinical investigation. Provisional 
evidence for appetite-stimulating properties also requires detailed investigation.  
 
Objectives 
To assess the tolerability of CBDA in locomotor activity, motor coordination and 
muscular strength tests, and additionally for ability to modulate feeding behaviours.   
  
Methods 
Male Lister hooded rats administered CBDA (0.05-5 mg/kg; p.o.) were assessed in 
habituated open field (for locomotor activity), static beam and grip strength tests. A 
further study investigated whether these CBDA doses modulated normal feeding 
behaviour. Finally, evidence of anxiolytic-like effects in the habituated open field 
prompted testing of 5 mg/kg CBDA for anxiolytic-like activity in unhabituated open 
field, light/dark box and novelty-supressed feeding (NSF) tests.   
 
Results 
 
CBDA had no adverse effects upon performance in any neuromotor tolerability test, 
however anxiolytic-like behaviour was observed in the habituated open field. Normal 
feeding behaviours were unaffected by any dose. CBDA (5 mg/kg) abolished the 
increased feeding latency in the NSF test induced by the 5-HT1AR antagonist, WAY-
100,635, indicative of anxiolytic-like effects, but had no effect on anxiety-like 
behaviour in the novel open field or light/dark box.  
 
Conclusions 
CBDA is very well tolerated and devoid of the sedative side-effect profile of 
benzodiazepines, justifying its clinical investigation as a novel AN treatment. 
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Introduction 
 
Chemotherapy treatment commonly causes distressing and debilitating side effects 
in cancer patients, including acute and delayed vomiting (Martin 1996); acute, 
delayed and anticipatory nausea (Rock et al. 2014b); reduced food intake and 
bodyweight (Hainsworth and Hesketh 1992); and fatigue (Ahlberg et al. 2003). These 
chemotherapy-induced nausea and vomiting (CINV) symptoms are highly distressing 
for patients, adversely affecting quality of life to the point where some will delay and 
even consider refusing future cycles of chemotherapy treatment (Janelsins et al. 
2013). It is estimated that, without prophylaxis, chemotherapy-induced nausea and 
vomiting (CINV) would be experienced by up to 80% of patients, with prevalence and 
severity varying according to the individual chemotherapy regimen employed (dos 
Santos et al. 2012). Many commonly prescribed chemotherapy drugs are classified 
as highly emetogenic within typical dose ranges, including cisplatin, 
cyclophosphamide (>1500mg/m2) and carmustine, all of which lead to CINV in >90% 
of patients without effective prophylaxis (Hesketh 2008; Roila et al. 2010). Cisplatin, 
the most extensively studied highly emetogenic chemotherapy drug, elicits a 
biphasic CINV response, comprising an acute phase (within 24 hours) and delayed 
phase (24-120 hours), each with distinct pathogeneses and sensitivities to anti-
emetic treatments (Martin 1996). 
 
The effective control of the acute phase of CINV is achieved in approximately half of 
patients undergoing highly emetic chemotherapy using 5-HT3 receptor antagonists 
(e.g. ondansetron) in combination with a glucocorticoid (e.g. dexamethasone). 
However, the delayed phase of CINV remains poorly controlled by this combination 
of drugs (Hickok et al. 2003). More recently, it has been shown that adjunctive use of 
neurokinin 1 (NK1) receptor antagonists (e.g. apripitant) with conventional anti-
emetic treatment regimens can significantly reduce the incidence of delayed vomiting 
(Navari et al. 1999; Campos et al. 2001; Hesketh et al. 2003). Indeed the 
combination therapy of NK1 receptor antagonist, 5HT3R antagonist and 
dexamethasone is now strongly recommended for CINV prophylaxis in highly 
emetogenic regimes as it provides complete control of vomiting in both the acute and 
delayed phases of CINV in 60-70% of patients (Kris et al. 2006; Roila et al. 2010). 
Despite these advances, the control of delayed nausea, and the consequences of 
incomplete control of acute and/or delayed vomiting, remain problematic and 
requires new antiemetic strategies (Hesketh 2008; Janelsins et al. 2013).  
 
Incomplete or ineffective control of nausea can cause increased anxiety, depression 
and the development of anticipatory nausea in patients (Rock et al. 2014b). 
Anticipatory nausea (AN) manifests as nausea (sometimes accompanied by 
vomiting) prior to administration of chemotherapy, and occurs in up to 20% of 
patients before any one chemotherapy cycle and in up to 30% of patients by the 
fourth cycle (Roscoe et al. 2011). AN is widely considered to be a form of Pavlovian 
classical conditioning, in which the cues of the clinical environment become 
associated with the nausea and vomiting induced by chemotherapy (Nesse et al. 
1980; Matteson et al. 2002) and, as such, is not controlled by standard antiemetic 
treatments (Janelsins et al. 2013; Kamen et al. 2014). Furthermore, once AN has 
developed, patients also report more severe acute nausea following subsequent 
cycles of chemotherapy (Bovbjerg 2006).  
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At present, treatment options for AN remain limited, with clinical recommendations 
focussed on prophylaxis against the initial manifestation of AN through adequate 
control of acute nausea and vomiting (Basch et al. 2012). In patients who develop 
AN due to a failure of adequate control, recommendations are limited to behavioural 
interventions such as systemic desensitisation and progressive muscle relaxation 
(Figueroa-Moseley et al. 2007), or the use of non-specific benzodiazepine anxiolytic 
drugs (Kamen et al. 2014). While behavioural interventions, in particular systemic 
desensitisation, are considered the most promising option currently available, a 
systematic review has highlighted the limited evidence for their efficacy (Lotfi-Jam et 
al. 2008). Furthermore, a lack of suitably trained personnel in treatment settings has 
been identified as an ongoing difficulty for the implementation of such interventions 
(Roscoe et al. 2011). The use of benzodiazepine anxiolytics is supported by two 
small clinical trials. Razavi et al. (1993) investigated the use of alprazolam as an 
adjunct to psychological support to prevent AN in 57 women undergoing adjuvant 
chemotherapy for breast cancer. They found a significant reduction in AN rate at 
second assessment (0% vs 18%), concluding alprazolam treatment delays the 
occurrence of AN. In a larger trial where lorazepam was administered with anti-
emetic therapy (metoclopramide, clemastine and dexamethasone) in 180 patients 
receiving high-dose cisplatin, Malik et al. (1995) reported a significantly higher 
complete response to AN in patients receiving lorazepam (52% vs 35%), however 
these patients also experienced significantly higher occurrences of sedation (92% vs 
37%) and amnesia (32% vs 1%). In addition to the debilitating side effects and 
dependency induced by benzopdiazepine treatment, their efficacy against AN is also 
reduced during multiple chemotherapy cycles (Roila et al. 2010). Thus, there 
remains an unmet clinical need for convenient, effective and well tolerated 
pharmacotherapies for AN.   
 
Recently, a number of pre-clinical studies have identified the non-psychoactive 
phytocannabinoid, cannabidiolic acid (CBDA), as a potential novel pharmacotherapy 
for the treatment of AN (Bolognini et al, 2013; Rock and Parker, 2013a; Rock and 
Parker, 2013b; Rock et al, 2014a). Parker and colleagues assessed the ability of 
CBDA and a number of other phytocannabinoids to prevent cisplatin- or lithium 
chloride (LiCl)-induced vomiting (a model of acute vomiting) in house musk shrews, 
and in rats to prevent LiCl-induced gaping (a model of acute nausea) or context-
induced gaping (a conditioned model of AN). The potential for these drugs to 
enhance saccharin palatability was also assessed in the latter model (see Rock et al, 
2014b for review of animal models). In studies using CBDA, low doses (0.01-0.5 
mg/kg; i.p.) attenuated acute vomiting in shrews, and both acute and anticipatory 
nausea in rats, with the latter effect blocked by the 5-HT1AR antagonist WAY-
100,635 (Bolognini et al. 2013). The same study reported an enhancement of 
saccharin palatability, as measured by unconditioned hedonic reactions. Further 
studies demonstrated that subthreshold doses of CBDA (0.1-0.5 µg/kg) potentiated 
the suppression of acute nausea by the anti-emetics ondansetron or metoclopramide 
(Rock and Parker 2013a; Rock and Parker 2013b). When CBDA was compared to 
the anti-emetic ondansetron or the benzodiazepine anxiolytic chlordiazepoxide 
(CDP) in the rat model of AN, both CBDA and CDP showed considerable efficacy, 
while ondansetron was ineffective (Rock et al. 2014a). Interestingly, in this study rats 
were tested in an activity chamber for 15 minutes immediately following the AN trial, 
which demonstrated the expected benzodiazepine-induced suppression of locomotor 
activity in rats treated with CDP, but not in those with CBDA. These studies 
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demonstrate that, in rodent models, CBDA is a highly potent treatment for both AN 
and acute nausea and vomiting. They also provide limited data to suggest CBDA 
may stimulate aspects of feeding under non-pathological conditions, and lack the 
sedative effects of benzodiazepine anxiolytics. 
 
To justify clinical investigation of CBDA as a novel AN treatment, it is crucial that the 
neuromotor tolerability profile is investigated in detail, to determine whether or not it 
elicits the side effects which have compromised the utility of benzodiazepines for this 
indication. Rock et al (2014a) have shown that CBDA does not supress spontaneous 
locomotor activity at doses ≤1 mg/kg, however this represents the sum total of 
published tolerability data for CBDA. To provide a more complete assessment of 
CBDA tolerability, the first part of our study administered CBDA to rats across a 
greater dose range (0.05-5 mg/kg), after which they completed a battery of tests for 
effects on locomotor activity, balance, fine motor control and muscular strength. The 
previously reported observation that CBDA enhanced unconditioned saccharin 
palatability raises the intriguing possibility that CBDA may directly stimulate feeding 
behaviour, and thus may have additional therapeutic potential for the attenuation of 
chemotherapy-induced anorexia and/or cancer cachexia. In the second part of our 
study, we directly assessed the potential hyperphagic actions of CBDA using a well-
established pre-feed paradigm for investigation of hyperphagic activity, which we 
have previously demonstrated for a number of other phytocannabinoids (Williams et 
al. 1998; Williams and Kirkham 2002; Farrimond et al. 2012a; Farrimond et al. 
2012b).  
Although the primary aims of this study were to determine the neuromotor tolerability 
and feeding behaviour profiles of CBDA, an additional follow-up experiment was also 
conducted to assess the anxiolytic effects of CBDA. During our battery of locomotor 
tasks, there was the suggestion of putative anxiolytic-like effects seen in the 
habituated open field test. As a final experiment therefore, using three tests of 
anxiety-like behaviour, CBDA was assessed alone and in combination with WAY-
100,635, a 5-HT1AR silent antagonist, as this receptor has previously been shown to 
block the effects of CBDA in models of acute and anticipatory nausea (Bolognini et 
al. 2013).    
 
 
Methods 
 
Drugs 
 
CBDA (GW Pharmaceuticals, UK) was dissolved directly into sesame oil (by 
sonication at room temperature) to a maximal working concentration of 5 mg/ml. 
Working solutions of 0.5 and 0.05 mg/ml were prepared by serial dilution in sesame 
seed oil. WAY-100,635 (Sigma-Aldrich, UK) was dissolved directly into sterile 0.9% 
saline vehicle (by vortex at room temperature), with a working concentration of 0.1 
mg/ml prepared from frozen aliquots of 1 mg/ml stock solution. All drugs were 
prepared freshly each test day and protected from light until administration.  
CBDA or sesame seed oil vehicle were administered per ora (p.o.) via a syringe 
placed into the cheek pouch at 1 ml/kg dosing volume, while WAY-100,635 or saline 
vehicle were administered intraperitoneally (i.p.) at an injection volume of 1 ml/kg.  
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Animals 
 
Young adult male Lister Hooded rats (Harlan, UK), weighing 200-225g on delivery, 
were housed in pairs in temperature and humidity controlled rooms with reversed 
light cycles (dim red light 12:00-24:00), with standard laboratory chow and water 
available ad libitum. A total of 60 rats were used in these experiments. All 
experiments were performed at the University of Reading in accordance with the 
principles of laboratory animal care, UK Home Office regulations [Animals (Scientific 
Procedures) Act 1986] and the ARRIVE guidelines for reporting experiments 
involving animals (Kilkenny et al. 2010; McGrath et al. 2010).  
 
Experimental Designs 
 
Experiments 1 and 2 (neuromotor tolerability and acute feeding tests) were 
conducted using a within-subjects design, with all experimental units (individual 
animals) receiving 0.05, 0.5 and 5.0 mg/kg CBDA and vehicle according to a 
pseudo-random, counterbalanced, Latin square protocol. All animals received doses 
separated by a minimum 48 hour washout period. On test days, animals were 
administered CBDA or vehicle 60 minutes prior to commencement of testing, 
consistent with our previously published studies of oral cannabinoid administration 
(Williams et al. 1998). 
 
 
Experiment 3 (anxiety-like behavioural tests) was conducted using a between-
subjects 2 x 2 design. Animals received either WAY-100,635 (0.1 mg/kg) or saline 
and either CBDA (5 mg/kg) or sesame seed oil vehicle to yield 4 groups: 
Saline/Vehicle, Saline/CBDA, WAY/Vehicle and WAY/CBDA. WAY-100,635 or saline 
were administered 15 minutes prior to CBDA or vehicle (as per Parker and 
colleagues’ protocol), with a further 60 minutes allowed for drug assimilation prior to 
commencement of testing. Animals were randomly allocated to the 4 treatment 
groups, and then further divided into 5 equally distributed blocks for daily testing, 
such that 2 animals from each group were tested on each day of the week, then 
again one week later. During the first week animals completed the open field and 
light/dark box tests consecutively in a single session, followed by the novelty-
supressed feeding test seven days later. The test order of groups was 
counterbalanced across the 5 test days each week.  
 
Experiment 1 Procedure (Neuromotor Tolerability) 
 
Prior to testing, animals (n=12) were subjected to a 5 day habituation process, 
consisting of daily handling, vehicle drug administration, and habituation to open field 
and static beam test procedures. On test days, all procedures were conducted 
during the first half of the dark period (12:00-18:00) in the same room as the animals 
were housed. All test equipment was cleaned with 70% ethanol and allowed to dry 
completely between animals. All tasks were presented in the following order with 
animals having a 5 minute rest period in their home cage between tasks.  
 
Open Field: consisting of a 1.1x1.1x0.4m black acrylic-lined box, delineated into 25 
equal squares to form a 3x3 central sector and a single square wide peripheral 
sector. The open field was illuminated by dim red light (~10 lx). Animals were placed 
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in the corner of the open field and left for 5 minutes with behaviour video recorded 
for offline coding using Observer XT software (Noldus, Netherlands). Locomotor 
activity was quantified based on the number of times animals crossed the lines on 
the open field floor, with time spent in the central area of the field and latency to first 
entry used to quantify anxiety-like behaviour (i.e. degree of thigmotaxis). It should be 
noted that the habituation animals received for this test is necessary for within-
subjects assessment of drug-induced changes of locomotor activity, however as a 
consequence the aversive / novel nature of the environment is attenuated. As such, 
a novel (i.e. unhabituated) open field test, as conducted in experiment 3, is more 
typically used when investigation of anxiety-like behaviour is the primary purpose of 
the test.   
 
Static Beam: The apparatus consisted of a 3.2cm diameter cylindrical beam, 1m long 
and 0.5m above floor level, with a bright light positioned at the start and an enclosed 
goal box at the end. Animals were placed at the start of the beam and allowed a 
maximum of 5 minutes to successfully traverse its length to reach the goal box. 
Animals were then given a 2 minute rest period in home cages prior to repeating the 
test. Tests were video recorded for offline coding using Observer XT software 
(Noldus, Netherlands). In the static beam test, performance generated four outcome 
measures, based on successful completion or length of beam traversed prior to 
falling (passrate and distance travelled), number of times paws were fully extended 
past the beam (foot slips) and time taken to traverse the middle 50cm of beam 
(speed). 
 
Forelimb Grip Strength: Animals completed two repeats of the forelimb grip strength 
test, separated by a 30 second rest period. Animals were placed with forelimbs 
gripping a trapeze bar connected to a digital force gauge (FH50, Sauter GmbH, 
Germany), then uniformly pulled by the tail base away from bar along the horizontal 
plane until grip was released and peak force recorded.  
 
Analysis: All behavioural coding was conducted by an experimenter blinded to 
treatment allocation. For static beam and forelimb grip strength outcome measures, 
where animals were subjected to 2 tests during the battery, data represent the mean 
of the two technical repeats, with the exception of pass rate on static beam in which 
a score of 0 - 2 was allocated based on number of successfully completed tests. All 
continuous data were analysed using SPSS 18 (IBM, UK) by one-way repeated 
measures ANOVA (ordinal pass rate data were analysed by Friedman’s ANOVA), 
with degrees of freedom and p-values corrected where assumptions of sphericity 
were violated (using Greenhouse-Geisser correction). When significant overall dose 
effects were observed, planned comparisons of all dose groups vs vehicle group 
were conducted to reveal any significant pairwise comparisons. Results were 
considered significant if p<0.05.  
 
 
Experiment 2 Procedure (Acute Feeding) 
 
Acute feeding experiments were conducted in pre-satiated animals according to a 
well-established paradigm for the detection of hyperphagia following administration 
of cannabinoids (Williams et al. 1998). Animals were habituated to handling (10 
days), vehicle dosing and the pre-feed procedure (7 days) and the testing apparatus 
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(5 days) prior to commencement of testing. The pre-feed procedure was conducted 
at the onset of the dark period, when animals (n=8) were transferred to individual 
cages containing 30.5±0.5 g of highly palatable wet-mash food. The wet-mash 
comprised 1 part Rat and Mouse Expanded Ground Diet (SDS, Witham, UK) and 
1.25 parts tap water. Animals were allowed 2 hours to consume the wet-mash, 
following which they were returned to their home cages and quantity of wet-mash 
consumed was measured. Animals were habituated to this pre-feed procedure until a 
stable consumption level was reached, as indicated by a non-significant main effect 
of test day by one-way ANOVA across 4 consecutive habituation days (F3, 28 = 0.653, 
p = 0.588).  
 
On test days, the pre-feed procedure was again conducted, immediately after which 
animals were administered CBDA or vehicle and replaced in home cages for 1 hour 
for drug assimilation, during which time food was unavailable. Animals were then 
placed into feeder cages for 2 hours, during which time food consumption and 
locomotor activity were recorded on automated food intake and infrared photobeam 
activity systems (TSE Systems, Germany and Ugo Basile, Italy respectively) and 
behaviour was video recorded. Animals were then returned to home cages at the 
end of the experiment, with food available ad libitum until the following test 
procedure ≥48 hours later. Quantity of food consumed was confirmed manually by 
weighing the remaining chow pellets in food hoppers and any crumbs in spillage 
trays below the cages, and subtracting these from the initial weight of chow in the 
hopper. The automated food intake system provided data output on the time, 
duration and size of each feeding bout, which were confirmed from video recordings 
as genuine feeding episodes as opposed to exploratory interactions with food 
hoppers. Feeding bouts were combined into ‘meals’, defined as feeding bouts 
consuming ≥0.5 g and separated by ≥900s, criteria previously shown to more 
accurately reflect the natural process of food consumption (Williams & Kirkham 
2002a; Farrimond et al. 2012b).  
 
Analysis: Data were analysed to provide measures of appetitive and consummatory 
behaviours, using the parameters of latency to first meal (appetitive) and meal sizes 
and durations (consummatory) in addition to total intake amounts. Ambulatory 
locomotor activity was quantified over the test duration using the number of infra-red 
beam breaks. All continuous data were analysed using SPSS 18 (IBM, UK) by one-
way repeated measures ANOVA, with degrees of freedom and p-values corrected 
where assumptions of sphericity were violated (using Greenhouse-Geisser 
correction). When significant overall dose effects were observed, planned 
comparisons of all dose groups vs vehicle group were conducted to reveal any 
significant pairwise comparisons. Results were considered significant if p<0.05.  
 
Experiment 3 Procedure (Unconditioned Anxiety Test Battery) 
 
Animals (n=40) were habituated to home environment and handling for 10 days prior 
to testing, and additionally to p.o. vehicle dosing and transfer to individual holding 
cages on the last two days of habituation. One day prior to the start of testing, all 
animals were tested for baseline levels of spontaneous locomotor activity, in which 
ambulatory activity was measured in an infrared photobeam activity cage (Ugo 
Basile, Italy) for 5 minutes. These data confirmed that randomisation to treatment 
group (as detailed above) had been successful, due to non-significant effects of 
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treatment group on baseline activity (F3, 36 = 1.342, p = 0.276) or bodyweight (F3, 36 = 
0.4829, p = 0.695).  
 
All testing was completed during the first half of the dark period (12:00-18:00) in the 
same room as the animals were normally housed. On test days, animals were 
administered drugs at 30 minute intervals from the onset of the dark period, such 
that all animals commenced testing 60 minutes after receiving CBDA / vehicle. 
Following drug administration, animals were placed in individual holding cages for 
the drug assimilation and inter-test rest periods. During testing in week 1, animals 
completed the open field test followed by the light/dark box test, separated by a 5 
minute rest period. During testing in week 2 (novelty-suppressed feeding), animals 
were food deprived in their home cages for 16-18 hours prior to testing (dependent 
on test order).  
 
Open Field: The open field test was conducted exactly as described for experiment 
1, however animals had not previously been habituated to the procedure/apparatus 
so the field represented a novel environment. Test data were analysed as described 
for experiment 1. 
 
Light/Dark Box: The apparatus consisted of an enclosed, black acrylic chamber (40 x 
40 x 20cm) connected via a small entrance hole to an open, white acrylic chamber of 
the same dimensions. The light sector was illuminated by a 60W white lamp such 
that light levels were ~500 lx, in contrast to ~5 lx in the dark sector. Animals were 
placed into the light chamber facing the entrance hole and behaviour was video 
recorded for 5 minutes. Animals were then returned to home cages and equipment 
was cleaned with 70% ethanol and allowed to dry completely. Movement between 
the sectors was recorded via an overhead digital video camera for subsequent offline 
coding using The Observer XT software (Noldus, The Netherlands), blinded to 
treatment group, with the number of entries and duration spent within the light sector 
quantified.  
 
Novelty-Suppressed Feeding: This task was conducted in a 1.1x1.1x0.4m white 
walled arena with a sawdust-covered floor. The field was illuminated by bright white 
light (~450 lx) and 10 standard chow pellets were placed on a large circular piece of 
filter paper in the centre. Animals were placed in the corner facing the centre and 
allowed a maximum of 10 minutes to begin feeding. Latency to onset of feeding 
(defined as pellet held in both paws and animals sat on haunches while eating) was 
timed manually and subsequently confirmed from the digital video recording of the 
test. As soon as an animal began feeding, it was removed from the open field and 
placed in an individual holding cage containing a weighed quantity of standard 
laboratory chow. It was allowed to feed ad libitum for 30 minutes, after which the 
quantity of food consumed was recorded and the animal was returned to its home 
cage. The test thus generated outcome measures of latency to feeding onset and 
post-test food intake.  
 
Analysis: For all outcome measures data were analysed by two-way independent 
ANOVA (CBDA x WAY). Where significant interactions were observed, follow-up 
analysis by one-way independent ANOVA and Tukey’s post-hoc comparisons were 
conducted. To avoid attrition bias resulting from missing data points due to technical 
errors in data capture (2 animals in light/dark box and 2 in novelty-suppressed 
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feeding), data were analysed on an intention-to-treat basis, with missing data 
replaced by simple imputation methods (group means). Analysis on a per protocol 
basis with all animals with missing data excluded did not alter the experiment’s 
conclusions. Results were considered significant at p<0.05.  
 
 
 
Results 
 
 
Experiment 1: Neuromotor tolerability tests 
 
To determine the viability of CBDA as a potential clinical candidate for the treatment 
of AN without the sedative effects typical of benzodiazapines, we first assessed its 
neuromotor tolerability profile using a battery of tests designed to reveal any effects 
on locomotor activity, balance and fine motor control and muscular strength. In 
addition to assessing locomotor activity, the habituated open field can provide an 
indication of any putative anxiolytic or anxiogenic activity. 
 
 
Open Field Test 
 
CBDA had no effect on locomotor activity at any dose when assessed in the open 
field test (Figure 1a), with no significant overall effect of dose observed for the 
number of lines crossed (F3, 33 = 0.405, p = 0.750). However, a significant attenuation 
of anxiety-like behaviour was apparent, with total time spent in the central sector 
(Figure 1b) increased with increasing CBDA dose (F3, 33 = 8.40, p < 0.0005). Planned 
comparisons revealed a significantly increased time spent in the central sector by 
both 0.5 mg / kg (p = 0.005) and 5.0 mg / kg (p < 0.0005) groups compared to 
vehicle-treated animals. In contrast, CBDA treatment had no effect upon latency to 
first entry into the central sector, a further measure of anxiety-like behaviour (F3, 33 = 
0.769, p = 0.52). 
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Fig. 1 Effects of CBDA treatment on behavioural parameters in habituated open field 
test, conducted as part of the neuromotor tolerability test battery (Experiment 1). 
Ambulatory locomotor activity (a) as measured by number of line crosses, was 
unaffected by any dose, however anxiolytic-like effects, as measured by increased 
time spent in central sector (b) were observed following 0.5 and 5.0 mg / kg CBDA  
treatment. Data presented as means ± SEM and analysed by one-way repeated 
measures ANOVA and planned comparisons (all groups vs vehicle), all groups n=12, 
** p < 0.01, *** p < 0.001 
 
 
Static Beam Test 
 
CBDA had no effect at any dose on any measure of balance or motor coordination 
as assessed in the static beam test (Table 1). Neither balance, as assessed by pass 
rate (Fr 3 = 3.522, p = 0.318), nor distance travelled (F3, 33 = 0.673, p = 0.574) were 
affected by CBDA treatment. Fine motor coordination was similarly unaffected, 
where CBDA treatment had no effect at any dose upon the number of foot slips 
made (F3, 33 = 0.605, p = 0.617) or time to cross the beam (F3,33 = 1.105, p = 0.361). 
 
Grip Strength Test 
 
The forelimb grip strength test (Table 1) for muscular strength and functional 
neurotoxicity revealed no significant overall dose effect of CBDA (F1.5, 16.2 = 1.109, p 
= 0.335). 
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CBDA (mg/kg) 0 0.05 0.5 5.0 
Static Beam Test     
 Pass rate (%) 100 95.8 95.8 100 
 
Distance Travelled (m) 
1.00 
(± 0.00) 
0.98 
(± 0.02) 
0.98 
(± 0.03) 
1.00 
(± 0.00) 
 
Footslips ( per m) 
1.17 
(± 0.26) 
1.14 
(± 0.29) 
0.73 
(± 0.28) 
1.04 
(± 0.14) 
 
Speed (m/s) 
0.174 
(± 0.019) 
0.151 
(± 0.022) 
0.180 
(± 0.017) 
0.133 
(± 0.020) 
Grip Strength Test     
 
Grip Strength (kgf) 
0.787 
(± 0.057) 
0.792 
(± 0.038) 
0.935 
(± 0.114) 
0.854 
(± 0.047) 
 
Table 1 Performance parameters in static beam and grip strength tests, conducted 
as part of the neuromotor tolerability test battery (Experiment 1). Data presented as 
means ± SEM, all groups n=12 
 
 
The results from experiment 1 demonstrate that CBDA, at doses up to 5 mg/kg, is 
well tolerated and exerts no deleterious effects on locomotor activity, balance, fine 
motor control or muscular strength. Furthermore, the dose-dependent increase in 
central sector duration suggests that CBDA may possess anxiolytic-like properties. 
These findings support its viability as a novel treatment of anticipatory nausea, 
without the neuromotor side effects typical of the benzodiazepine anxiolytics 
currently in clinical use. In light of this favourable tolerability profile, the ability of 
CBDA to stimulate feeding behaviours was investigated using the same dose range 
employed in Experiment 1.  
 
Experiment 2: Test of hyperphagia in pre-satiated rats 
 
To determine whether previously reported increases in saccharin palatability 
following CBDA administration were indicative of hyperphagic properties, we 
investigated the effects of CBDA on feeding behaviour in pre-satiated rats. As shown 
in Figure 2a, CBDA dose exerted no significant overall effect on total food intake 
during the 2 hour test period (F1.4, 9.5 = 0.336, p = 0.641). There was also no 
significant overall effect of CBDA dose on ambulatory locomotor activity (Figure 2b) 
within the feeding chambers (F3, 21 = 0.309, p = 0.819), further validating our findings 
in the habituated open field test.  
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Fig. 2 Food intake and ambulatory locomotor activity during 2 hour feeding test in 
pre-satiated rats (Experiment 2). CBDA had no effect on total chow consumed (a) or 
total locomotor activity (b) at any dose. Data presented as mean ± SEM and 
analysed by one-way repeated measures ANOVA, all groups n=8  
 
 
A more granular analysis of meal pattern microstructure parameters (Figure 3) 
revealed no significant overall effect of CBDA dose on latency to Meals 1 or 2 (F3, 21 
= 0.348, p = 0.791 and F3, 21 = 0.546, p = 0.656 respectively), size of meals (Meal 1: 
F3, 21 = 0.709, p = 0.557; Meal 2: F3, 21 = 0.541, p = 0.659) or duration of meals (Meal 
1: F1.5, 10.4 = 0.832, p = 0.429; Meal 2: F3, 21 = 0.821, p = 0.399). That the latency to 
first feeding episode was approximately 90 minutes into the test session for all 
groups demonstrates that the pre-satiation procedure was effective, and further 
corroborates the lack of CBDA effect on total food intake. 
 
12 
 
 
 Fig. 3 Graphic summary of meal pattern microstructure parameters from Experiment 2. Left 
edge of boxes positioned along x-axis according to meal latencies, box widths scaled to meal 
durations and meal sizes given above. CBDA had no effect on any of these measures at any 
dose. Note that no animals consumed a second meal in the 0.05 mg / kg group hence this 
box is omitted from the figure, and group mean meal sizes below the 0.5g meal criteria reflect 
that a number of animals consumed only ≤ 1 meal. Data presented as means and analysed 
by one-way repeated measures ANOVA, all groups n=8 
 
 
The results of Experiment 2 demonstrate that CBDA, in the dose range tested, did 
not modulate any aspect of feeding behaviour in pre-satiated rats. Based on the 
results from Experiments 1 and 2, a further study was conducted to assess whether 
the putative anxiolytic-like effect of CBDA could be validated in the novel open field 
and light/dark box tests. Additionally, CBDA was assessed in the novelty-suppressed 
feeding test, to investigate whether motivation to eat could be increased under 
anxiogenic-like conditions which typically suppress feeding behaviour. The 5-HT1AR 
activation-dependent mechanism previously reported for CBDA in the AN model 
(Bolognini et al. 2013) led us to further investigate whether any anxiolytic-like effects 
were sensitive to 5-HT1AR antagonist challenge in these tests.   
 
     
Experiment 3: Anxiety-like behaviour tests 
 
Open Field Test 
 
The total time spent in the central sector of the open field did not show significant 
main effects of either CBDA (F1, 36 = 0.177, p = 0.676) or WAY-100,635 
administration (F1, 36 = 0.156, p = 0.695), nor was any interaction observed (F1, 36 = 
0.042, p = 0.838). Locomotor activity within the open field, as measured by the 
number of line crosses, again did not show significant main effects of either CBDA 
(F1, 36 = 2.908, p = 0.097) or WAY-100,635 administration (F1, 36 = 0.613, p = 0.439), 
nor was any interaction observed (F1, 36 = 0.391, p = 0.536). However, a significant 
interaction was observed between the effects of WAY-100,635 and CBDA (F1, 36 = 
5.270, p = 0.028) on latency to first entry into the central sector. Further analysis of 
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this interaction using one-way ANOVA did not show a significant overall effect of 
treatment group (F3, 36 = 1.879, p = 0.151) or any significant pairwise comparisons, 
indicating a lack of meaningful drug effect. 
 
 
Light / Dark Box Test 
 
The number of entries into the light sector of the box did not show significant main 
effects of CBDA (F1, 36 = 1.677, p = 0.204) or WAY-100,635 (F1, 36 = 0.995, p = 
0.325), nor was any interaction observed (F1, 36 = 0.379, p = 0.542). The total time 
spent in the light sector of the box did not show significant main effects of CBDA (F1, 
36 = 1.096, p = 0.302) or WAY-100,635 (F1, 36 = 0.237, p = 0.629), nor was any 
interaction observed (F1, 36 = 0.501, p = 0.484).  
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Fig. 4 Effects of CBDA (5 mg/kg) and the 5-HT1AR antagonist WAY-100,635 (0.1 
mg/kg) in the novelty-supressed feeding test, conducted in a modified open field as 
14 
 
part of the anxiety-like behaviour test battery (Experiment 3). Treatment with WAY-
100,635 alone elicited an anxiogenic-like effect by increasing latency to feeding 
onset, which was abolished by co-treatment with CBDA (a). Home cage food intake 
in the 30 minutes following the test was unaffected by either drug (b). Data 
presented as means ± SEM and analysed by two-way ANOVA, followed by one-way 
ANOVA and Tukey’s post-hoc comparisons, all groups n=10, * p < 0.05, *** p < 
0.001 
 
 
Novelty-Suppressed Feeding Test 
 
A significant interaction was observed between the effects of CBDA and WAY-
100,635 (F1, 36 = 7.551, p = 0.009) on latency to onset of feeding (figure 4a). Follow-
up analysis revealed a significant overall effect of treatment group (F3, 36 = 10.619, p 
< 0.0005), due to an increased latency to feed in animals treated with WAY-100,635 
alone vs vehicle control animals (p = 0.017) or those treated with CBDA alone (p < 
0.0005). This increased latency was completely abolished in animals treated with 
both CBDA and WAY-100,635 (p < 0.0005). Post-test food intake in home cages 
(figure 4b) did not show significant main effects of either CBDA (F1, 36 = 1.266, p = 
0.268) or WAY-100,635 administration (F1, 36 = 2.056, p = 0.160), nor was any 
interaction observed (F1, 36 = 1.811, p = 0.187). The lack of effect of either drug on 
post-test food intake indicates that their effect on latency to feed was due to 
modulation of anxiety-like behaviour alone, and not confounded by effects on 
appetite.   
 
 
 
Discussion 
 
Our results suggest CBDA is well-tolerated, since it failed to produce any neuromotor 
side effects at any dose tested. In the same dose range, CBDA also had no 
modulatory effect on feeding behaviour in healthy, pre-satiated rats. However, CBDA 
did abolish the potentiated suppression of feeding behaviour in the NSF test induced 
by the 5-HT1AR antagonist WAY-100,635. Thus, CBDA does not appear to increase 
appetite per se, but may selectively stimulate feeding under putatively anxiogenic 
conditions which suppress feeding behaviour, possibly via 5-HT1AR-mediated 
mechanisms.   
 
The battery of neuromotor tolerability tests used in this study has previously been 
utilised to assess other phytocannabinoids against drugs with known clinical 
neuromotor side effects (Hill et al. 2012; Hill et al. 2013). The benzodiazepine class 
of drugs, which are used clinically to attenuate AN, cause significant sedative side 
effects, decrease activity in the OFT (reviewed in Prut and Belzung, 2003) and 
impair performance in the static beam (Stanley et al. 2005) and forelimb grip strength  
assays (Meyer et al. 1979; Ferguson and Paule 1996). Thus, these tests have 
predictive validity for assessment of the neuromotor tolerability profile of novel 
compounds for AN treatment. In our experiments, CBDA did not affect activity in the 
open field or cause any detrimental effects on any performance measure in either 
static beam or grip strength tests at any dose tested, the range of which was 
comparable to that used in previous studies in models of acute and anticipatory 
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nausea. The lack of effect on locomotor activity in the OFT is consistent with a 
previously published report that CBDA (0.0001-1 mg/kg; i.p.) did not affect distance 
travelled in a 15 minute activity chamber test (Rock et al. 2014a), although doses of 
the benzodiazepine CDP which supressed AN (5-10mg / kg) exerted a sedative 
effect in this test. The observation that ambulatory locomotor activity during the 
duration of the feeding test (Experiment 2) was also unaffected by any dose of 
CBDA further confirms the lack of sedative effect, even over an extended test period 
(2 hours) - considerably longer than that typically used for activity tests (Curzon et al. 
2009). The present study extended the investigation of potential sedative effects to 
include measures of motor coordination, using the static (walking) beam assay, 
which can more sensitively predict clinical sedative effects than the more commonly 
used rotarod test (Stanley et al. 2005; Hill et al. 2012). CBDA had no effect at any 
dose on performance measures of balance or fine motor control in this test. The final 
component of the tolerability test battery, the forelimb grip strength test, 
demonstrated that CBDA administration did not result in drug-induced muscle 
relaxation at any dose. These results validate and considerably extend the 
preliminary evidence for the lack of sedative effects of CBDA, supporting its potential 
as a novel treatment for AN unlikely to have the compromised clinical utility of 
benzodiazepines (Malik et al. 1995; Rock et al. 2014b).  
 
A previously published study of the effects of CBDA in the AN model reported 
increased unconditioned hedonic reactions to saccharin (i.e. increased palatability), 
which the authors speculated could indicate an appetite-enhancing effect (Bolognini 
et al. 2013). Such an effect could have an additional clinical utility by attenuating the 
comorbid anorectic effects of chemotherapy treatment (Hainsworth and Hesketh 
1992) and/or cancer anorexia-cachexia syndrome (Stephens and Fearon 2008).  
To investigate whether this suggestion of an appetite-enhancing effect could first be 
validated in healthy rats under more naturalistic feeding conditions (than intraoral 
cannula-delivered saccharin responses), Experiment 2 was conducted using a well-
established test of hyperphagia. The acute feeding test in pre-satiated rats has been 
utilised in many previous studies in our lab to sensitively determine hyperphagic 
actions of pharmacological compounds, providing detailed information on both food 
intake and the microstructure of meal patterns (Williams et al. 1998; Williams and 
Kirkham 2002; Farrimond et al. 2010a; Farrimond et al. 2010b; Farrimond et al. 
2012a). In vehicle-dosed rats, feeding behaviour during the test period is minimal, 
typically comprising 1-2 small meals with a total consumption of ≤1g, occurring after 
~90 minutes (Farrimond et al. 2012b). Consistent with this typical baseline level of 
consumption, no significant effect was seen on total food intake following 
administration of any dose of CBDA, with rats consuming 0.4-1g over 2 hours. The 
latency to consumption of the first meal, a measure of appetitive feeding behaviour 
(motivation to eat) was similarly unaffected by CBDA treatment, and neither were 
consummatory behaviour measures of meal size or duration. These data indicate 
that, at oral doses of 0.05 - 5 mg/kg, CBDA does not modulate total food intake or 
any aspects of meal microstructure. This is in contrast to the reported effect on 
saccharin palatability, however it should be noted that the previously reported effect 
was only seen at 0.01mg/kg, but not at 0.1 - 5 mg/kg, and furthermore the 
behavioural model  and route of administration were also different (Bolognini et al. 
2013). It therefore remains possible that CBDA may have appetite stimulating effects 
only at very low doses, or selectively for hedonic foods over regular chow, however 
the present data does not support any effects on feeding behaviour at doses ≥0.05 
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mg/kg. However, in light of the effects seen in the NSF test presented here, it may 
be the case that (at least at higher doses) CBDA selectively stimulates feeding under 
putatively anxiogenic conditions, which is more consistent with the positive effects 
seen in the AN model, and may be more clinically useful. As such, further 
investigation of CBDA actions on feeding in models of chemotherapy- or anxiety-
induced anorexia are warranted.    
 
An interesting observation made during the neuromotor tolerability study was the 
dose-dependent increase in the time rats spent in the central sector of the habituated 
open field. This test was primarily designed as a test of sedative / stimulant effects, 
and hence rats were habituated to the open field to achieve stable baseline activity 
prior to CBDA administration. However the lack of locomotor activity modulation in 
this test (as measured by line crosses) suggests this observation may still be 
indicative of an anxiolytic-like effect. Cannabidiol (CBD), produced by spontaneous 
decarboxylation of CBDA (Cluny et al. 2011), has well documented anxiolytic-like 
effects in both animals and humans (reviewed by Schier et al, 2012) which appears 
to be primarily facilitated by 5-HT1AR-mediated neurotransmission (Campos et al. 
2012). However, to the best of our knowledge, only a single study of the anxiolytic-
like effects of CBDA has been published to date. In this study, CBDA (0.001-1 
mg/kg, i.p.) was assessed for the ability to attenuate conditioned freezing to a shock-
paired tone, however expression of conditioned freezing was not modified by any 
dose (Rock et al. 2014a). The suggestion of an anxiolytic-like effect of CBDA in the 
habituated open field test, and the paucity of published data in anxiety-like 
behavioural models for this cannabinoid, prompted us to further investigate the 
effects of CBDA in three typical models of unconditioned anxiety-like behaviour. As 
the greatest effect in the habituated open field was seen following administration of 5 
mg/kg CBDA, and previous reports implicated indirect 5-HT1AR activation in AN 
models (Bolognini et al. 2013; Rock et al. 2014a), we investigated this dose with and 
without pre-treatment with the selective 5-HT1AR antagonist WAY-100,635, at the 
same dose used by Parker and colleagues as a behaviourally silent antagonist in 
their AN studies. In the novel (unhabituated) open field test, the more aversive 
nature of the environment was apparent from both the reduced central sector 
duration in control rats (16s vs 24s in the habituated OFT) and number of line 
crosses (96 vs 157 in the habituated OFT). However, in this test CBDA had no effect 
on central sector duration or number of line crosses, suggesting that in this more 
aversive environment CBDA did not have significant anxiolytic-like effects, and thus 
CBDA has limited, if any, efficacy within this test. Consistent with the results from the 
novel open field, in the light / dark box test, which is another test based on the 
conflict between rats’ exploratory drive and fear of bright or exposed areas (Bourin 
and Hascoët 2003), CBDA also had no effect on either number of entries or duration 
spent in the light sector, which would be indicative of an anxiolytic-like effect. In both 
tests, administration of 0.1 mg/kg WAY-100,635, alone or in combination with CBDA, 
also had no effect on any measure of anxiety-like behaviour or general locomotor 
activity. This indicates that this dose, which was behaviourally silent in previous AN 
studies, was also appropriate as a silent antagonist challenge in the open field and 
light / dark box tests, and that no interaction occurred with CBDA relevant to 
behavioural outcomes in these tests.  
 
A third test of anxiety-like behaviour was conducted using the novelty-supressed 
feeding (or hyponeophagia) test, which differs from the open field and light/dark box 
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tests in that the conflict arises between the innate aversion to bright unfamiliar 
spaces and the desire to feed (following a period of food deprivation) rather than to 
explore a novel environment (Britton and Britton 1981; Dulawa and Hen 2005). The 
NSF test is sensitive to numerous drugs with known anxiolytic activity, including the 
5-HT1AR agonist 8-OH-DPAT (Rex et al. 1998; Zhang et al. 2010) and also 
demonstrates the anxiogenic-like activity of the 5-HT1AR antagonist NAN-190 (Zhang 
et al. 2010) and increased anxiety-like behaviour in 5-HT1AR knockout mice (Gross 
et al. 2000). In the present study, treatment with CBDA alone did not affect the 
latency to feed, however WAY-100,635 treatment alone significantly increased 
latency, indicative of an anxiogenic-like effect. That administration of WAY-100,635 
alone had an anxiogenic-like effect in this test was unexpected, given that the dose 
of this compound was chosen as a behaviourally-silent antagonist challenge, which 
had no effect in either previous AN studies (Bolognini et al. 2013), or in the novel 
open field or light/dark box tests in the present study. While this increased latency is 
consistent with the work of Zhang et al.(2010) using the 5-HT1AR antagonist NAN-
190, it should also be noted that a 0.3 mg/kg dose of WAY-100,635 given to mice in 
the NSF test was behaviourally silent (Duvvuri et al. 2009), and that in other tests of 
anxiety-like behaviour this compound can be anxiogenic or even anxiolytic 
dependent on dose and test type (Sánchez 1996; Griebel et al. 1999; Griebel et al. 
2000). Interestingly, in rats which were administered both CBDA and WAY-100,635 
in the present NSF test, this anxiogenic-like effect of WAY-100,635 was completely 
abolished. The results from the post-test home cage intake test did not show 
significant effects of either drug, or their combination, ruling out confounding effects 
on appetite, consistent with results from the acute feeding study. Similarly, the lack 
of effect of either drug on the number of line crosses in the novel open field test rules 
out possible confounding effects of locomotor activity modulation. It thus appears 
that this dose of WAY-100,635, while behaviourally-silent in the open field and 
light/dark box tests, elicits an anxiogenic-like response in the NSF test, and that this 
response is antagonised by CBDA, despite it this cannabinoid having no anxiolytic-
like effect when administered alone. Such pharmacological effects, while seemingly 
robust in terms of the data obtained, are less than straightforward to interpret based 
on the present experiments alone. 
 
Previous studies demonstrated that while the ability of CBDA to attenuate nausea is 
abolished by pretreatment with WAY-100,635, in vitro binding experiments 
suggested this is via an indirect enhancement of 5-HT1AR activation rather than 
direct activation (Bolognini et al. 2013). The results from experiment 3 thus provides 
some further support for the notion that CBDA has limited efficacy as a typical 5-
HT1AR agonist anxiolytic, but under certain anxiogenic conditions does possess 
anxiolytic-like activity, presumably via indirect modulation of 5-HT1AR-mediated 
neurotransmission. While beyond the scope of the present study, it may be valuable 
to further characterise the locus and mechanism of this activity.  
 
The present report provides vital further data in support of CBDA as a novel 
treatment for anticipatory nausea, which is unlikely to elicit the compromising 
sedative effects of the benzodiazepine anxiolytics currently in clinical use. CBDA 
appears to have some anxiolytic-like activity, specific to models of feeding 
suppression or nausea involving alterations in 5-HT1AR-dependent 
neurotransmission. CBDA did not modulate feeding behaviour in healthy rats, 
however these and previous data suggest beneficial effects on feeding may occur 
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under pathological anxiogenic conditions, further investigation of which is warranted. 
While such investigations may provide evidence of further therapeutic potential for 
such conditions, the tolerability data presented here strongly supports clinical 
investigation of CBDA as a non-sedative alternative to benzodiazepine anxiolytics for 
the treatment of AN.  
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